Express News | YS Biopharma Receives 180 Day Extension By Nasdaq To Regain Compliance With Minimum Bid Price Rule
BenzingaApr 29 08:02 ET
YS Biopharma Reports 9M Results
Seeking AlphaApr 19 17:35 ET
Earnings Call Summary | YS Biopharma(YS.US) Q3 2024 Earnings Conference
The following is a summary of the YS Biopharma Co., Ltd. (YS) Q3 2024 Earnings Call Transcript:Financial Performance:YS Biopharma reported a total revenue of RMB 438.1 million for the first nine month
moomoo AIApr 19 09:16 ET · Conference Call
Express News | YS Biopharma Co 9M 2024 EPS Loss Of RMB (1.04) Versus RMB (2.71) YoY
Moomoo 24/7Apr 19 07:13 ET
Express News | YS Biopharma Co 9M 2024 Sales Of $61.9M
Moomoo 24/7Apr 19 07:12 ET
Press Release: YS Biopharma Announces Unaudited Financial Results for the First Nine Months of Fiscal Year 2024
Dr. David Shao continued, "At the corporate level, since late 2023 we have embarked on a comprehensive series of initiatives aimed at fortifying our foundation for future growth.
Dow JonesApr 19 07:00 ET
YS Biopharma Granted Phase I Clinical Trial License Of Therapeutic Chronic Hepatitis B Virus Vaccine
YS Biopharma Co., Ltd. (NASDAQ:YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines
BenzingaApr 18 08:11 ET
YS Biopharma to Report First Nine Months of Fiscal Year 2024 Financial Results on April 19, 2024
The Company's management will hold an earnings conference call at 8:00 A.M. Eastern Time on Friday, April 19, 2024 to discuss the financial results. Listeners may access the call by dialing the following numbers:
PR NewswireApr 16 08:00 ET
Chinese Biotech YS Biopharma's Next-Gen Rabies Vaccine Non-Inferior To Approved Competitor
Tuesday, YS Biopharma Co Ltd (NASDAQ:YS) revealed interim results from the ongoing Phase 3 clinical trial of its next-generation PIKA Rabies Vaccine. The interim results indicate that the PIKA Rabies
BenzingaApr 9 15:30 ET
Express News | YS Biopharma Shares Are Trading Lower. The Company Announced Interim Results From the Ongoing Phase 3 Clinical Trial of Its PIKA Rabies Vaccine
Moomoo 24/7Apr 9 08:15 ET
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
GainersAcrivon Therapeutics (NASDAQ:ACRV) stock moved upwards by 72.3% to $10.19 during Tuesday's pre-market session. The market value of their outstanding shares is at $230.5 million. Biophytis (NASD
BenzingaApr 9 08:09 ET
Express News | YS Biopharma Highlights Interim Results Of Pivotal Phase 3 Clinical Study Of PIKA Rabies Vaccine; Says Results Indicate That The Pika Rabies Vaccine Has Successfully Met The Primary Endpoints Of The Trial
Moomoo 24/7Apr 9 08:09 ET
YS Biopharma Announces Positive Interim Results of Pivotal Phase 3 Clinical Study of PIKA Rabies Vaccine
GAITHERSBURG, Md., April 9, 2024 /PRNewswire/ -- YS Biopharma Co., Ltd. (Nasdaq: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced positive interim results from the ongoing Phase 3 clinical trial (the "Phase 3 Trial" or the "Trial") of its next-generation PIKA Rabies Vaccine.
YS BiopharmaApr 9 00:00 ET
YS Biopharma Announces Full Repayment of $40M Loan Facility
Seeking AlphaApr 3 08:49 ET
12 Health Care Stocks Moving In Thursday's Pre-Market Session
GainersAvalo Therapeutics (NASDAQ:AVTX) shares rose 328.2% to $20.34 during Thursday's pre-market session. The company's market cap stands at $16.3 million. Xilio Therapeutics (NASDAQ:XLO) stock moved
BenzingaMar 28 08:06 ET
12 Health Care Stocks Moving In Tuesday's After-Market Session
GainersNKGen Biotech (NASDAQ:NKGN) stock increased by 62.4% to $1.4 during Tuesday's after-market session. The company's market cap stands at $30.6 million. vTv Therapeutics (NASDAQ:VTVT) stock moved
BenzingaMar 5 16:31 ET
YS Biopharma Announces Results of Extraordinary General Meeting Held on February 22, 2024
YS Biopharma Co., Ltd. (Nasdaq: YS) today announced the results of its extraordinary general meeting (the "EGM") held on February 22, 2024 in Hong Kong.
PR NewswireFeb 22 17:00 ET
YS Biopharma Announces Results of Extraordinary General Meeting and Responds to False Statements About the Meeting
GAITHERSBURG, Md., Feb. 16, 2024 /PRNewswire/ -- YS Biopharma Co., Ltd. (Nasdaq: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufa
PR NewswireFeb 16 20:20 ET
Press Release: Shareholders Led by Yi Zhang Announce Successful Results of Removal of Directors and Election of New Directors of YS Biopharma Co., Ltd.
Shareholders Led by Yi Zhang Announce Successful Results of Removal of Directors and Election of New Directors of YS Biopharma Co., Ltd. PR Newswire NEW YORK, Feb. 16, 2024 NEW YORK, Feb. 16, 2024
Dow JonesFeb 16 17:36 ET
Express News | YS Biopharma Appoints Six New Members To Its Board, Effective February 13, 2024; Names Ajit Shetty As Chairperson
Moomoo 24/7Feb 14 07:52 ET
No Data
No Data